drugset / Trial / NCT02194283

Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers

NCT02194283

Phase 1 Completed 34 enrolled Boehringer Ingelheim
RandomizedSingle-groupDouble-blindTreatment

Summary

The main objectives of the present study are to determine pharmacokinetics of ambroxol in healthy male volunteers following repeated administration of lozenges of 20 mg ambroxol for four days

Timeline

Start
2009-10
Primary completion
2009-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ambroxol Small molecule 20 mg Oral
Subject Ambroxol Small molecule 40 mg Oral
Subject Ambroxol Small molecule 80 mg Oral

Indications

No indication recorded.